Suppr超能文献

醛脱氢酶 1 阳性癌症干细胞介导炎症性乳腺癌的转移和不良临床结局。

Aldehyde dehydrogenase 1-positive cancer stem cells mediate metastasis and poor clinical outcome in inflammatory breast cancer.

机构信息

Department of Molecular Oncology, Institut Paoli-Calmettes/UMR891 Institut National de la Sante et de la Recherche Medicale, Université de la Méditerranée, Marseille Cancer Research Center, Marseille, France.

出版信息

Clin Cancer Res. 2010 Jan 1;16(1):45-55. doi: 10.1158/1078-0432.CCR-09-1630. Epub 2009 Dec 22.

Abstract

PURPOSE

To examine the role of cancer stem cells (CSC) in mediating metastasis in inflammatory breast cancer (IBC) and the association of these cells with patient outcome in this aggressive type of breast cancer.

EXPERIMENTAL DESIGN

CSCs were isolated from SUM149 and MARY-X, an IBC cell line and primary xenograft, by virtue of increased aldehyde dehydrogenase (ALDH) activity as assessed by the ALDEFLUOR assay. Invasion and metastasis of CSC populations were assessed by in vitro and mouse xenograft assays. Expression of ALDH1 was determined on a retrospective series of 109 IBC patients and this was correlated with histoclinical data. All statistical tests were two sided. Log-rank tests using Kaplan-Meier analysis were used to determine the correlation of ALDH1 expression with development of metastasis and patient outcome.

RESULTS

Both in vitro and xenograft assays showed that invasion and metastasis in IBC are mediated by a cellular component that displays ALDH activity. Furthermore, expression of ALDH1 in IBC was an independent predictive factor for early metastasis and decreased survival in this patient population.

CONCLUSIONS

These results suggest that the metastatic, aggressive behavior of IBC may be mediated by a CSC component that displays ALDH enzymatic activity. ALDH1 expression represents the first independent prognostic marker to predict metastasis and poor patient outcome in IBC. The results illustrate how stem cell research can translate into clinical practice in the IBC field.

摘要

目的

研究癌症干细胞(CSC)在介导炎性乳腺癌(IBC)转移中的作用,以及这些细胞与这种侵袭性乳腺癌患者预后的关系。

实验设计

通过 ALDEFLUOR 分析评估醛脱氢酶(ALDH)活性增加,从 SUM149 和 MARY-X(一种 IBC 细胞系和原代异种移植物)中分离 CSC。通过体外和小鼠异种移植实验评估 CSC 群体的侵袭和转移。在 109 例 IBC 患者的回顾性系列中测定 ALDH1 的表达,并将其与组织临床数据相关联。所有统计检验均为双侧。使用 Kaplan-Meier 分析的对数秩检验用于确定 ALDH1 表达与转移的发展和患者预后的相关性。

结果

体外和异种移植实验均表明,IBC 的侵袭和转移是由具有 ALDH 活性的细胞成分介导的。此外,IBC 中 ALDH1 的表达是该患者群体早期转移和生存降低的独立预测因素。

结论

这些结果表明,IBC 的转移、侵袭性行为可能由具有 ALDH 酶活性的 CSC 成分介导。ALDH1 表达是预测 IBC 转移和患者预后不良的第一个独立预后标志物。这些结果说明了干细胞研究如何转化为 IBC 领域的临床实践。

相似文献

1
Aldehyde dehydrogenase 1-positive cancer stem cells mediate metastasis and poor clinical outcome in inflammatory breast cancer.
Clin Cancer Res. 2010 Jan 1;16(1):45-55. doi: 10.1158/1078-0432.CCR-09-1630. Epub 2009 Dec 22.
4
Aldehyde dehydrogenase 1 expression in inflammatory breast cancer as measured by immunohistochemical staining.
Clin Breast Cancer. 2014 Jun;14(3):e81-8. doi: 10.1016/j.clbc.2013.12.006. Epub 2013 Dec 27.
5
Aldehyde dehydrogenase 1 is a tumor stem cell-associated marker in lung cancer.
Mol Cancer Res. 2009 Mar;7(3):330-8. doi: 10.1158/1541-7786.MCR-08-0393. Epub 2009 Mar 10.
6
The ALDH1⁺ subpopulation of the human NMFH-1 cell line exhibits cancer stem-like characteristics.
Oncol Rep. 2015 May;33(5):2291-8. doi: 10.3892/or.2015.3842. Epub 2015 Mar 9.
8
Targeting ALDH(bright) human carcinoma-initiating cells with ALDH1A1-specific CD8⁺ T cells.
Clin Cancer Res. 2011 Oct 1;17(19):6174-84. doi: 10.1158/1078-0432.CCR-11-1111. Epub 2011 Aug 19.
10

引用本文的文献

1
Cancer stem cells: Bridging microenvironmental interactions and clinical therapy.
Clin Transl Med. 2025 Jul;15(7):e70406. doi: 10.1002/ctm2.70406.
3
AXL promotes inflammatory breast cancer progression by regulating immunosuppressive macrophage polarization.
Breast Cancer Res. 2025 May 6;27(1):70. doi: 10.1186/s13058-025-02015-8.
4
ALDH1A1 in breast cancer: A prospective target to overcome therapy resistance (Review).
Oncol Lett. 2025 Mar 4;29(5):213. doi: 10.3892/ol.2025.14959. eCollection 2025 May.
7
Circular RNAs in cancer stem cells: Insights into their roles and mechanisms (Review).
Int J Mol Med. 2025 Mar;55(3). doi: 10.3892/ijmm.2025.5491. Epub 2025 Jan 24.
8
Unveiling the link between chronic inflammation and cancer.
Metabol Open. 2025 Jan 9;25:100347. doi: 10.1016/j.metop.2025.100347. eCollection 2025 Mar.
10
Telomerase inhibition in breast cancer and breast cancer stem cells: a brief review.
Med Oncol. 2024 Nov 25;42(1):14. doi: 10.1007/s12032-024-02562-8.

本文引用的文献

1
Molecular targets for treatment of inflammatory breast cancer.
Nat Rev Clin Oncol. 2009 Jul;6(7):387-94. doi: 10.1038/nrclinonc.2009.73. Epub 2009 May 26.
2
Differentiation therapy of acute myeloid leukemia: past, present and future.
Curr Opin Hematol. 2009 Mar;16(2):84-91. doi: 10.1097/MOH.0b013e3283257aee.
4
Breast cancer cell lines contain functional cancer stem cells with metastatic capacity and a distinct molecular signature.
Cancer Res. 2009 Feb 15;69(4):1302-13. doi: 10.1158/0008-5472.CAN-08-2741. Epub 2009 Feb 3.
5
Cancer stem cells are everywhere.
Nat Med. 2009 Jan;15(1):23. doi: 10.1038/nm0109-23.
6
Efficient tumour formation by single human melanoma cells.
Nature. 2008 Dec 4;456(7222):593-8. doi: 10.1038/nature07567.
7
Breast cancer stem cell markers - the rocky road to clinical applications.
Breast Cancer Res. 2008;10(5):110. doi: 10.1186/bcr2130. Epub 2008 Sep 15.
8
The lymphovascular embolus of inflammatory breast cancer expresses a stem cell-like phenotype.
Am J Pathol. 2008 Aug;173(2):561-74. doi: 10.2353/ajpath.2008.071214. Epub 2008 Jul 3.
9
The CD44+/CD24- phenotype is enriched in basal-like breast tumors.
Breast Cancer Res. 2008;10(3):R53. doi: 10.1186/bcr2108. Epub 2008 Jun 17.
10
Meta-analysis confirms BCL2 is an independent prognostic marker in breast cancer.
BMC Cancer. 2008 May 29;8:153. doi: 10.1186/1471-2407-8-153.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验